Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Glenmark_Pharmaceuticals
gptkb:AMGN gptkb:Biocon_Limited gptkb:Teva_Europe gptkb:Sun_Pharmaceutical_Industries |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:are |
a topic of ongoing research
a focus of international collaborations used in autoimmune diseases considered a sustainable option subject to market competition part of global health initiatives a focus of Biocon's R& D efforts a growing segment of the pharmaceutical market a key area for investment by Biocon a part of Biocon's portfolio a response to the high cost of biologics a solution for unmet medical needs an alternative to traditional drugs developed through biological processes expected to expand in the next decade gaining popularity in emerging markets increasingly used in oncology influenced by healthcare policies involved in global supply chains not identical to reference products part of personalized medicine produced in living systems subject to patent litigation subject to post-marketing surveillance therapeutically equivalent to reference products used in diabetes management used in hematology |
| gptkbp:benefits |
patent expirations
|
| gptkbp:can_be |
interchanged with reference products
|
| gptkbp:clinical_trial |
gptkb:Biocon
|
| gptkbp:developed_by |
gptkb:Biocon
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biosimilars
|
| gptkbp:impact |
healthcare costs
|
| gptkbp:includes |
gptkb:Company
growth factors monoclonal antibodies fusion proteins biosimilar adalimumab biosimilar filgrastim biosimilar pegfilgrastim biosimilar rituximab biosimilar trastuzumab |
| gptkbp:is_involved_in |
cell culture techniques
protein purification processes |
| gptkbp:is_similar_to |
reference biologics
|
| gptkbp:is_subject_to |
regulatory guidelines
interchangeability studies |
| gptkbp:is_used_for |
treatment of diseases
|
| gptkbp:manufacturer |
gptkb:Biocon
|
| gptkbp:marketed_as |
various brand names
|
| gptkbp:price |
original biologics
|
| gptkbp:promotes |
patient access to therapies
|
| gptkbp:regulates |
gptkb:EMA
|
| gptkbp:requires |
quality assurance measures
comparative clinical studies |
| gptkbp:targets |
chronic diseases
|